Measurement of free thyroxin (FT4) by a recently introduced commercial assay (Amerlex5 Free T4 RIA) was compared with the calculated free thyroxin index (FT4I) for serum from 104 postpartum women. Of these, 63 had transient thyroid dysfunction due to autoimmune thyroiditis, six had transient Graves' thyrotoxicosis, and 35 were euthyroid with no signs of autoimmune thyroid disease. The correlation between results for FT4 and the calculated FT4I for 95 serum samples from women with no signs of autoimmune thyroiditis (r = 0.941 ; p = 0.0001) was almost identical to that for 270 serum samples from women with thyroid microsomal autoantibodies characteristic of autoimmune thyroiditis (r = 0.937; p = 0.0001). Furthermore, we observed no difference when the autoimmune group was subdivided according to low or high titers of thyroid microsomal antibodies. In no case did autoantibodies to thyroxin interfere with the FT4 assay. However, one woman had a spuriously low value for FT4I owing to interference by autoantibodies to triiodothyronine with the triiodothyronine resin uptake test. We conclude that the FT4 AlA assay provided diagnostic information in this group of postpartum women equivalent to that of the more elaborate procedure of determining FT4I.
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Recently, commercial radioimmunoassay (RIA) methods have become available for directly measuring free thyroxin (FF4). Because equilibrium dialysis techniques are not ideal for routine laboratory use, and because calculations of FF4 index require two separate laboratory procedures and still provide only an indirect estimate of FF4 concentrations, replacing both of these techniques with direct determination of FF4 should be an improvement.
One of the commercial RIAs for FF4, the Amerlex5 Free T4 RIA (1), is based on the use of a so-far-undisclosed labeled thyroxin (T4) analog, chemically modified to inhibit binding to the normally occurring thyroxin-binding proteins in serum. In the assay, endogenous FF4 and this labeled T4 analog compete for binding to a high-avidity antibody. Thus, interference from thyroxin-binding autoantibodies could result in falsely high FF4 values, as has been reported in several cases (2) (3) (4) (5) (6) , most of which had concomitant signs of autoimmune thyroiditis. For this reason the usefulness of the FF4 assay may be limited in the diagnosis of autoimmune thyroid dysfunction.
In 
Materials and Methods
Our report is based on two separate investigations of thyroid function in women after delivery.
The first, designed to ascertain the prevalence of thyroid dysfunction and autoiminune thyroid disease in 460 women selected at random, has been presented in detail previously (7) .
In short, FF4 and thyroid microsomal antibodies (MsAb) in serum were measured two and five months postpartum, and serum thyrotropin five months after delivery. Women with MsAb and (or) abnormal thyroid function were reexamined repeatedly. We measured T4, triiodothyronine (T3), and T3-resin uptake in all serum samples from women with FF4 11 or 21 pmoliL or who had had detectable MsAb on at least one occasion.
For the second investigation we selected another group of 20 women in whom MsAb in serum were detected in early pregnancy. Every six weeks after they delivered we measured thyrotropin, T4, T3, T3-uptake, and MsAb in their serum. Altogether, we studied 95 serum samples from 41 MsAb-negative women and 274 samples from 63 MsAbpositive women from these two investigations.
Aliquots of serum from all examined women were stored at -20 #{176}C until analysis for FF4, which we performed within a year, using the Amerlex Free T4 RIA (Amersham International Ltd., Bucks., U.K.) and assaying samples from the same patient in duplicate in the same run. The withinassay coefficients of variation (CV) for three control serum pools (20 assays) were 4.4%, 3.6%, and 3.5% for FF4 concentrations of 2.7, 15.4, and 45.7 pmolJL, respectively. The between-assay CV was 6.3%, 6.3%, and 8.6% for the same respective concentrations.
We used the following commercial RIAs for the various analytes in serum (our normal reference interval is listed in parentheses): T4 (57-145 nmolJL) by "TetraTab RIA", Nuclear Medical Labs. Inc., Dallas, TX); T3 (1.2-2.9 nmol/L), 'l'riiodothyronine RIA", Farmos Diagnostica, Turku, Finland; thyrotropin (<5 milli-int. unitsfL), "Quantitope TSH", Kallestad Labs., Austin, TX; and T3-uptake (75-115% of the resin uptake of pooled serum), determined with Sephadex as adsorbent according to a modification of the method described by Hansen (9) . FF41 (57-145) was calculated as the product of the T4 and T3-uptake values. MsAb were detected with Thymune-M (Wellcome Ltd., Beckenham, U.K.). We followed exactly the assay procedures recommended by the manufacturers of the reagent kits and used the standards provided. No woman in the study was on medication known to interfere with secretion and metabolism of thyroid hormones.
For statistical analyses we calculated correlation coefficients by the method of least squares and we used Student's t-test for unpaired data.
Results
No signs of thyroid disease were seen in 409(88.9%) of the 460 randomly selected women, who were examined two and five months after delivery. Their serum FF4 values were within the normal reference interval given by the manufacturer ( The correlation between total T4 and FF4 was 0.709 (p = 0.000 1) in the MsAb-negative group and 0.852 (p = 0.001) in the MsAb-positive group. One MsAb-positive woman with autoantibodies to T3 was excluded from the calculations for reasons discussed below.
Discussion
We found the RIA for FF4 to be a simple, reliable method for screening for thyroid dysfunction in postpartum women.
We chose to study the postpartum period for two reasons. Firstly, there is a high prevalence of thyroid function abnormalities, both thyrotoxicosis and hypothyroidism, dur- ing the first year after delivery (7, 8) . In many cases only minor changes occur; consequently, one can observe a relatively large number of borderline function values in both the thyrotoxic and the hypothyroid range. Secondly, screening for MsAb allowed us to evaluate the influence of autoimmune thyroiditis on the FF4 assay in a large population group. We found a close correlation between FF4 and FF41 in both the MsAb-negative and the MsAb-positive groups. With the assay methods used, the presence of interfering T4-binding autoantibodies would have led to spuriously high FF4 values and low T4 and FF41 values. In fact, however, we observed only one deviating case among the 63 women with demonstrable MsAb titers. This woman had T3 values that were unexpectedly low throughout the postpartum period despite her passing through the typical thyrotoxic and hypothyroid phases of autoinunune postpartum thyroiditis. She was found to have antibodies binding to T3, probably producing T3-uptake values that were misleadingly low (this being most evident in the thyrotoxic phase), and leading to the discrepancy between the results for FF4 and FF41.
From this study, therefore, we conclude that interference with the FF4 assay by T4 autoantibodies is rare, as is the presence of autoantibodies that influence the RIAs for total T3 or T4 (11). Nonetheless, these results do not exclude the presence of T4-autoantibodies in some patients; but only when antibodies are present in high amounts or have high avidity will enough of the tracer be sequestered to affect the FF4 determinations (4).
Therecent demonstration of a high frequency of euthyroid
sick syndrome when the FF4 assay is used in hospital patients (12) may give rise to diagnostic difficulties. The simplicity of the FF4 assay may then be counterbalanced by the need for complementary investigation procedures. However, women investigated in the postpartum period do not usually have signs of intercurrent illness and this problem was not encountered in the present study.
